Aridis Pharmaceuticals, Inc. ARDS

ARDS Company Overview

Aridis Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of anti-infective therapies for life-threatening bacterial and viral infections. The company has historically concentrated on monoclonal antibody therapeutics, inhaled anti-infective treatments, and immune-based approaches intended to address infections associated with antibiotic resistance and hospital-acquired pathogens. Aridis has operated primarily within the biopharmaceutical and infectious disease sectors, targeting areas where existing treatment options are limited or where resistance to standard antibiotics has become a significant clinical concern.

The company’s principal programs have included monoclonal antibody candidates directed at pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa, as well as investigational therapies related to respiratory infections. Aridis has also pursued proprietary drug formulation and delivery technologies intended to improve treatment efficacy in pulmonary disease settings. Founded in 2003 and headquartered in California, United States, the company evolved from a platform-based anti-infectives developer into a clinical-stage biotechnology company focused on precision immunotherapies and adjunctive infectious disease treatments. Public disclosures and market filings indicate that the company has experienced financial and operational restructuring pressures in recent years, and some development programs have faced delays or strategic reevaluation.